JDRF Blog

Latest in Research News

  • A Win for the European T1D Community: Zynquista (sotagliflozin) Approved for Type 1 Diabetes

    April 29, 2019

    In a second win for the type 1 diabetes (T1D) community, the European Commission has approved Zynquista™ (sotagliflozin) for use in adults...

  • What is nPOD?

    April 17, 2019

    The human pancreas is very difficult to study, as JDRF-funded scientists well know. It cannot be imaged or safely biopsied from a...

  • European Commission Has Approved Forxiga for Adults with Type 1 Diabetes

    March 25, 2019

    It’s official: The European Commission has approved Forxiga® (dapagliflozin and marketed in the United States as Farxiga®) for adults with type 1...

  • Can a Snail Hold the Key to Better Blood Sugar Control?

    February 26, 2019

    “Rapid-acting” insulin analogs were introduced commercially in the 1990s; however, these insulins are still slower than insulin secreted from a nondiabetic pancreas,...

  • In First-In-Human Tests, New Artificial Pancreas System Smartphone App Shows Reliable Glucose Control

    February 25, 2019

    Artificial pancreas (AP) systems “close the loop” between continuous glucose monitors and insulin pumps, using a computer algorithm to calculate and administer...

  • Video Preview: World-Renowned Researchers Gather at the nPOD Annual Meeting (February 19-22)

    February 15, 2019

    At the Network for Pancreatic Organ Donors with Diabetes (nPOD) Meeting—its 11th annual and taking place February 19-22—more than 215 people are...

  • T1D Diagnosis? Gut Bacteria May Hold the Clue

    February 14, 2019

    Over the past 50 years, type 1 diabetes (T1D) has increased significantly in many developed countries around the world. There is a...

  • SGLT Inhibition: It’s Not Just for Type 2 Anymore

    February 8, 2019

    SGLT inhibition may soon be approved for use for people with type 1 diabetes Can a drug long-used for type 2 diabetes,...

  • Maybe it’ll Work for Type 1: Clinical Trial Results Announced

    February 1, 2019

    A protein, called glucokinase (or GK), acts as a key regulator of sugar levels in the body, and its expression is limited to tissues that require sugar-sensing, mainly the liver and pancreatic beta cells. If blood glucose levels are deemed too high, activation of GK in the liver increases glucose utilization which in turn lowers blood glucose.

  • JDRF Leads Push to Develop a Vaccine for Viral Infections that Could Trigger T1D

    January 31, 2019

    Scientists worldwide are attempting to determine why some people predisposed to type 1 diabetes (T1D) eventually end up developing the disease. There...